# Immunogenicity and Safety Study of Allantoic Split Inactivated Seasonal Influenza Vaccine (VSI)

> **NCT03016143** · PHASE2 · COMPLETED · sponsor: **Research Institute for Biological Safety Problems** · enrollment: 300 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Allantoic Split Inactivated Seasonal flu Vaccine
- **BIOLOGICAL:** VAXIGRIP

## Key facts

- **NCT ID:** NCT03016143
- **Lead sponsor:** Research Institute for Biological Safety Problems
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2016-11
- **Final completion:** 2016-12
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2018-06-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03016143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03016143, "Immunogenicity and Safety Study of Allantoic Split Inactivated Seasonal Influenza Vaccine (VSI)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03016143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*